2026-04-29T04:09:48Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186882025-03-21T09:40:47Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Ramos-Rincon, Jose-Manuel author López-Carmona, María-Dolores author Cobos-Palacios, Lidia author López-Sampalo, Almudena author Rubio-Rivas, Manuel author Martín-Escalante, María-Dolores author de-Cossio-Tejido, Santiago author Taboada-Martínez, María-Luisa author Muiño-Miguez, Antonio author Areses-Manrique, Maria author Martinez-Cilleros, Carmen author Tuñón-de-Almeida, Carlota author Abella-Vázquez, Lucy author Martínez-Gonzalez, Angel-Luís author Díez-García, Luis-Felipe author Ripper, Carlos-Jorge author Asensi, Víctor author Martinez-Pascual, Angeles author Guisado-Vasco, Pablo author Lumbreras-Bermejo, Carlos author Gómez-Huelgas, Ricardo author On Behalf Of The Semi-Covid-Network, author 2022-06-29 Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19. 2077-0383 http://hdl.handle.net/10668/21309 http://hdl.handle.net/20.500.12105/18688 35807058 10.3390/jcm11133769 Journal of clinical medicine COVID-19 SARS-CoV-2 Spain Age ≥ 80 Mortality Remdesivir Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.